peptide backbone raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-22. Anything still debated is marked as such rather than presented as settled.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Approximate composition of the free peptide |
| Molecular weight | Approximately 4813 Da | Calculated for the free base |
| Structural class | Synthetic linear peptide | 39 residues with modified backbone |
| Solubility | Soluble in water and polar solvents | Behavior of the lyophilized solid |
| Typical storage temperature | -20 degrees Celsius or below | Solid form, protected from light |
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
Universal supports. In a more recent, more convenient, and more widely used method, the synthesis starts with the universal support where a non-nucleosidic linker is attached to the solid support material (compounds 1 and 2). A phosphoramidite respective to the 3'-terminal nucleoside residue is coupled to the universal solid support in the first synthetic cycle of oligonucleotide chain assembly using the standard protocols. The chain assembly is then continued until the completion, after which the solid support-bound oligonucleotide is deprotected. The characteristic feature of the universal solid supports is that the release of the oligonucleotides occurs by the hydrolytic cleavage of a P-O bond that attaches the 3'-O of the 3'-terminal nucleotide residue to the universal linker as shown in Scheme 6. The critical advantage of this approach is that the same solid support is used irrespectively of the sequence of the oligonucleotide to be synthesized. For the complete removal of the linker and the 3'-terminal phosphate from the assembled oligonucleotide, the solid support 1 and several similar solid supports require gaseous ammonia, aqueous ammonium hydroxide, aqueous methylamine, or their mixture and are commercially available. The solid support 2 requires a solution of ammonia in anhydrous methanol and is also commercially available. Nucleosidic solid supports. In a historically first and still popular approach, the 3'-hydroxy group of the 3'-terminal nucleoside residue is attached to the solid support via, most often, 3'-O-succinyl arm as in compound 3.
As the hernia progresses, contents of the abdominal cavity, such as the intestines, can descend into the hernia and run the risk of being pinched within the hernia, causing an intestinal obstruction. Significant pain at the hernia site is suggestive of a more severe course, such as incarceration (the hernia cannot be reduced back into the abdomen) and subsequent ischemia and strangulation (when the hernia becomes deprived of blood supply). If the blood supply of the portion of the intestine caught in the hernia is compromised, the hernia is deemed "strangulated" and gut ischemia and gangrene can result, with potentially fatal consequences. The timing of complications is not predictable.
== Treatment == For patients with VWD type 1 and VWD type 2A, desmopressin is available as different preparations, recommended for use in cases of trauma, or in preparation for dental or surgical procedures. Desmopressin stimulates the release of VWF from the Weibel–Palade bodies of endothelial cells, thereby increasing the levels of VWF (as well as coagulant factor VIII) three- to five-fold. Desmopressin is also available as a preparation for intranasal administration (Stimate) and as a preparation for intravenous administration. Desmopressin is contraindicated in VWD type 2b because of the risk of aggravated thrombocytopenia and thrombotic complications. Desmopressin is probably not effective in VWD type 2M and is rarely effective in VWD type 2N. It is totally ineffective in VWD type 3. Regular preventative infusions of desmopressin to keep vWF levels normal (outside of planned surgical procedures or trauma) is not recommended. However, in very small limited studies, preventative desmopressin infusions have been shown to prevent bleeding episodes in severe VWD. For women with heavy menstrual bleeding, estrogen-containing oral contraceptive medications are effective in reducing the frequency and duration of the menstrual periods. Estrogen and progesterone compounds available for use in the correction of menorrhagia include ethinylestradiol, levonorgestrel, drospirenone and cyproterone.
== Beamhouse operations == The steps in the production of leather between curing and tanning are collectively referred to as beamhouse operations. They include, in order, soaking, liming, removal of extraneous tissues (unhairing, scudding and fleshing), deliming, bating or puering, drenching, and pickling.
The first fast reactor built and operated was the Los Alamos Plutonium Fast Reactor ("Clementine") in Los Alamos, NM. Clementine was fueled by Ga-stabilized delta-phase Pu and cooled with mercury. It contained a 'window' of Th-232 in anticipation of breeding experiments, but no reports were made available regarding this feature. Another proposed fast reactor is a fast molten salt reactor, in which the molten salt's moderating properties are insignificant. This is typically achieved by replacing the light metal fluorides (e.g. LiF, BeF2) in the salt carrier with heavier metal chlorides (e.g., KCl, RbCl, ZrCl4). Several prototype FBRs have been built, ranging in electrical output from a few light bulbs' equivalent (EBR-I, 1951) to over 1,000 MWe. As of 2006, the technology is not economically competitive to thermal reactor technology, but India, Japan, China, South Korea, and Russia are all committing substantial research funds to further development of fast breeder reactors, anticipating that rising uranium prices will change this in the long term. Germany, in contrast, abandoned the technology due to safety concerns. The SNR-300 fast breeder reactor was completed in 1985 but did not obtain authorization to start up. The project was cancelled in March 1991.
Sources: en.wikipedia.org
=== Saddiction and hiatus (2024–present) === At the beginning of February 2024, Hangman's Chair returned to perform at Le Mondial du Tatouage – Tattoo Planetarium, which brought together 500 tattoo artists from around the world, at Paris' Grande halle de la Villette. In October 2024, the band released the single "2 am Thoughts" and its music video, taken from the upcoming seventh album, Saddiction. "2 am Thoughts" features a guest appearance from Raven van Dorst of Dool. The music video follows Nackphouminh, the original singer of Hangman's Chair, through a day in his life, three years after he adopted a healthier lifestyle combining sport and spiritual exploration. He is the author of the video's closing line. The band went on a European tour with Dool in October 2024. They released the single "Kowloon Lights" in November. Saddiction was released on 14 February 2025 through Nuclear Blast Records, with the group's lineup remaining unchanged: Chanut, Thépegnier, Hanvic, and Toufouti. A Loner and Saddiction would be part of a new trilogy. The album entered at number 13 on the French SNEP–SCPP Rock and Metal Chart compiled by the OCC. Mathieu David of Rolling Stone France wrote that Hangman's Chair "continues to weave their simultaneously heavy and hovering ambiences amidst mysterious urban landscapes". He added that while A Loner "hovered at 10,000 feet in an ethereal cloud, Saddiction brings back the riffs, not without reminding the harshest ambiences of Banlieue Triste". Other singles followed: "In Disguise", "Healed?", and "The Worst is Yet to Come".
Several former employees of the company have claimed of poor workplace conditions, including the start of the workweek on Sunday to cooperate with Chinese time zones and excessive workload. Employees claimed they averaged 85 hours of meetings per week and would frequently stay up all night in order to complete tasks. Some employees claimed the workplace's schedule operated similarly to the 996 schedule. The company has a stated policy of working from 10 AM to 7 PM five days per week (63 hours per week), but employees noted that it was encouraged for employees to work after hours. One female worker complained that the company did not allow her adequate time to change her feminine hygiene product because of back-to-back meetings. Another employee noted that working at the company caused her to seek marriage therapy and lose an unhealthy amount of weight. In response to the allegations, the company noted that they were committed to allowing employees "support and flexibility". In September 2023, two former ByteDance employees filed a formal complaint with the US Equal Employment Opportunity Commission (EEOC) asking the EEOC to investigate TikTok's practice of retaliation against workers who complain about discrimination.
== In hypoxic/anoxic conditions == As oxygen is fundamental for oxidative phosphorylation, a shortage in O2 level can alter ATP production rates. The proton motive force and ATP production can be maintained by intracellular acidosis. Cytosolic protons that have accumulated with ATP hydrolysis and lactic acidosis can freely diffuse across the mitochondrial outer-membrane and acidify the inter-membrane space, hence directly contributing to the proton motive force and ATP production. When exposed to hypoxia/anoxia (no oxygen), most animals will see damage done to their mitochondria. From some species, these conditions can happen due to environmental variables, such as low tides, low temperatures, or general living conditions, like living in a hypoxic underground burrow. In humans, these conditions are commonly met in medical emergencies such as strokes, ischemia, and asphyxia.
Argentine President Cristina Fernández de Kirchner posthumously promoted her to the rank of general. Javiera Carrera was also a significant figure in the Chilean War of Independence, who used her family influence and status to form social groups of women to advocate for independence. Carrera sewed the first Chilean flag as a sign of their independence and endured imprisonment multiple times in her life as a result of her great contributions. She is seen as one of the main female figures in Chilean Independence. Another significant figure in documenting the experiences of women during the Independence Wars was Marquita Sanchez, also known as Madame Mendeville. Sanchez recorded many of her experiences during the Argentine Independence War while also recording accounts of her daily life as a female activist during this period in history. She also helped record several events and battles central to the Argentine military and their continued fighting against the Spanish. According to gender stereotypes, women were not meant to be soldiers; only men were supposed to engage in fighting and conflict. There were still plenty of women present on the battlefields to help rescue and nurse soldiers. Some women fought alongside their husbands and sons on the battlefield. The majority of women assumed supportive and non-competitive roles such as fundraising and caring for the sick. Revolution for women meant something different from for men. Women saw revolution as a way to earn equal rights, such as voting, and to overcome the suppression and subordination of women to men.
=== Mechanism of action === The important interaction between phosphate and magnesium ions makes magnesium essential to the basic nucleic acid chemistry of all cells of all known living organisms. More than 300 enzymes require magnesium ions for their catalytic action, including all enzymes using or synthesizing ATP and those that use other nucleotides to synthesize DNA and RNA. The ATP molecule is normally found in a chelate with a magnesium ion.
Sources: en.wikipedia.org
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.
Single-receptor agents act predominantly at GLP-1R. Tirzepatide retains activity at GIPR, which is expressed in pancreatic islets, adipose tissue, and the central nervous system. The contribution of each receptor to the overall response is still an area of active study, and the relative weight of GIPR signaling in humans is not fully settled.
The fatty diacid moiety binds serum albumin, which reduces renal filtration of the active peptide. Additional resistance to enzymatic breakdown comes from non-natural residues in the backbone. Together these features produce an apparent half-life of about five days and permit weekly dosing intervals.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.